{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:46:17Z","timestamp":1792658777376,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/qai.0b013e3181b0328f","type":"journal-article","created":{"date-parts":[[2009,8,20]],"date-time":"2009-08-20T07:13:50Z","timestamp":1250752430000},"page":"64-69","source":"Crossref","is-referenced-by-count":12,"title":["Reversible Reduction of Nevirapine Plasma Concentrations During Rifampicin Treatment in Patients Coinfected With HIV-1 and Tuberculosis"],"prefix":"10.1097","volume":"52","author":[{"given":"Alberto","family":"Matteelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuccia","family":"Saleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Bonkoungou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Cristina C","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seni","family":"Kouanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie J","family":"Sanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Simpor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Monno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Carosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Regazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin","family":"Dembele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-9-20210131","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(06)68383-9","article-title":"Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment.","volume":"367","author":"Corbett","year":"2006","journal-title":"Lancet"},{"key":"R3-9-20210131","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/518660","article-title":"Tuberculosis and HIV infection: the global setting.","volume":"196","author":"Nunn","year":"2007","journal-title":"J Infect Dis"},{"key":"R4-9-20210131","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0140-6736(04)17141-9","article-title":"Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.","volume":"364","author":"Jindani","year":"2004","journal-title":"Lancet"},{"key":"R5-9-20210131","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2125.2004.02265.x","article-title":"Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes.","volume":"59","author":"Glaeser","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R6-9-20210131","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00002030-199912030-00029","article-title":"Effect of tuberculosis therapy on nevirapine trough plasma concentrations.","volume":"13","author":"Dean","year":"1999","journal-title":"AIDS"},{"key":"R7-9-20210131","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","article-title":"Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.","volume":"28","author":"Ribera","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-9-20210131","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/135965350501000809","article-title":"Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.","volume":"10","author":"Autar","year":"2005","journal-title":"Antivir Ther"},{"key":"R9-9-20210131","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1086\/505210","article-title":"Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.","volume":"43","author":"Manosuthi","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R10-9-20210131","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.qai.0000214808.75594.73","article-title":"Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.","volume":"42","author":"Ramachandran","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R11-9-20210131","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/dkm484","article-title":"Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.","volume":"61","author":"Cohen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R12-9-20210131","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/QAD.0b013e32814e6b08","article-title":"Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.","volume":"21","author":"Hoffman","year":"2007","journal-title":"AIDS"},{"key":"R15-9-20210131","first-page":"4","article-title":"Updated guidelines to perform therapeutic monitoring for antiretroviral agents.","volume":"3","author":"la Porte","year":"2006","journal-title":"Rev Antivir Ther"},{"key":"R16-9-20210131","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1086\/510078","article-title":"Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.","volume":"44","author":"Manosuthi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R17-9-20210131","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1468-1293.2007.00432.x","article-title":"Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.","volume":"8","author":"Penzak","year":"2007","journal-title":"HIV Med"},{"key":"R18-9-20210131","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00002030-200303070-00024","article-title":"Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis.","volume":"17","author":"Oliva","year":"2003","journal-title":"AIDS"},{"key":"R19-9-20210131","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcome of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.","volume":"300","author":"Boulle","year":"2008","journal-title":"JAMA"},{"key":"R20-9-20210131","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00002030-200106150-00003","article-title":"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1 infected individuals.","volume":"15","author":"Veldkamp","year":"2001","journal-title":"AIDS"},{"key":"R21-9-20210131","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/infdis\/171.3.537","article-title":"High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.","volume":"171","author":"Havlir","year":"1995","journal-title":"J Infect Dis"},{"key":"R22-9-20210131","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1468-1293.2008.00563.x","article-title":"Standard-dose efavirenz vs standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.","volume":"9","author":"Manosuthi","year":"2008","journal-title":"HIV Med"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200909010-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T23:36:07Z","timestamp":1710545767000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200909010-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181b0328f","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}